Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongming Pan

Showing results (181-190 of 262) with videos related to

Pageof 27
Sort By:
Scientific Reports|April 16, 2014
JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagyXinbing Sui, Na Kong, Xian Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 8, 2026
SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in ChinaShun Lu, Jian Fang, Yan Yu, et al.
Frontiers in Immunology|October 17, 2022
Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapyJiawei Shou, Fan Mo, Shanshan Zhang, et al.
BMC Cancer|April 10, 2024
First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumorsYe Guo, Zishu Wang, Huan Zhou, et al.
BMC Medicine|September 29, 2023
A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysisYaxin Liu, Wei Wang, Rutie Yin, et al.
The Lancet. Gastroenterology & Hepatology|October 9, 2021
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trialRui-Hua Xu, Yanqiao Zhang, Hongming Pan, et al.
Frontiers in Immunology|October 28, 2022
Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 studyLu Si, Xiaoshi Zhang, Yongqian Shu, et al.
British Journal of Cancer|December 4, 2025
Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancerNoboru Yamamoto, Dong Yan, Vinod Ganju, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2012
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trialAnn-Lii Cheng, Zhongzhen Guan, Zhendong Chen, et al.
Future Oncology (London, England)|August 18, 2018
Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III studyJin Li, Ruihua Xu, Shukui Qin, et al.
Pageof 27

Showing results (181-190 of 262) with videos related to

Sort By:
Pageof 27
Scientific Reports|April 16, 2014
JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagyXinbing Sui, Na Kong, Xian Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 8, 2026
SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer in ChinaShun Lu, Jian Fang, Yan Yu, et al.
Frontiers in Immunology|October 17, 2022
Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapyJiawei Shou, Fan Mo, Shanshan Zhang, et al.
BMC Cancer|April 10, 2024
First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumorsYe Guo, Zishu Wang, Huan Zhou, et al.
BMC Medicine|September 29, 2023
A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysisYaxin Liu, Wei Wang, Rutie Yin, et al.
The Lancet. Gastroenterology & Hepatology|October 9, 2021
Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trialRui-Hua Xu, Yanqiao Zhang, Hongming Pan, et al.
Frontiers in Immunology|October 28, 2022
Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 studyLu Si, Xiaoshi Zhang, Yongqian Shu, et al.
British Journal of Cancer|December 4, 2025
Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancerNoboru Yamamoto, Dong Yan, Vinod Ganju, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2012
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trialAnn-Lii Cheng, Zhongzhen Guan, Zhendong Chen, et al.
Future Oncology (London, England)|August 18, 2018
Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III studyJin Li, Ruihua Xu, Shukui Qin, et al.
Pageof 27